Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
1988-10-24
pubmed:abstractText
The mechanism of action of an abrin 9.2.27 antimelanoma antibody conjugate has been studied in 2 human melanoma cell lines, FEMX and LOX, which differ in sensitivity to the immunotoxin (IT) and to native abrin. The IT, which had been affinity purified before use to remove molecules with exposed gal-binding sites on the toxin B-chain, inhibited cellular protein synthesis at a faster rate in the LOX than in the FEMX cells despite the fact that the LOX cells express less specific antigen and bind less IT to the cell surface. Surface-bound abrin-IT, as well as surface-bound specific antibody, disappeared at equal rates from the cell surface of the 2 cell lines. After binding of labelled IT the disappearance of total cell-associated radioactivity, as well as the appearance of TCA-precipitable and TCA-soluble radioactivity in the incubation medium, occurred at faster rates in the LOX than in the FEMX cells. No free abrin or antibody B-chain complex could be detected in the medium or inside the cells. The results indicate that the different sensitivities of the melanoma cell lines reflect different abilities to process endocytosed IT and to translocate the active A-chain to the cytosol. Experiments carried out in the presence of lactose are interpreted to mean that the A-chain may be translocated to the cytosol by two mechanisms, one involving antigen-antibody interaction and one involving the B-chain, and that the lectin binding site contributes to the B-chain-facilitated mechanism.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Sep
pubmed:issn
0020-7136
pubmed:author
pubmed:issnType
Print
pubmed:day
15
pubmed:volume
42
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
400-4
pubmed:dateRevised
2007-7-24
pubmed:meshHeading
pubmed:year
1988
pubmed:articleTitle
Kinetics of uptake and degradation of an abrin immunotoxin by melanoma cells and studies of the rates of cellular intoxication.
pubmed:affiliation
Institute for Cancer Research, Norwegian Radium Hospital, Montebello, Oslo.
pubmed:publicationType
Journal Article